Anti-inflammatory and anti-aging effects of hydroxytyrosol on human dermal fibroblasts (HDFs)

0301 basic medicine 03 medical and health sciences 3. Good health
DOI: 10.1186/s41702-018-0031-x Publication Date: 2018-07-24T14:00:45Z
ABSTRACT
Hydroxytyrosol is discovered in a form of elenolic acid ester oleuropein in olive leaf and oil. The anti-carcinogenic, antioxidant, and anti-inflammatory effects of hydroxytyrosol have been reported in the food, medical, pharmaceutical, and life science fields. But it has not been studied on skin biology field. This study is demonstrated using UVA-induced cellular aging model of human dermal fibroblast. The cell survival rate was measured using the principle of water-soluble tetrazolium salt-1 assay, which is a measurement method for cell survival rate. The quantitative real-time PCR (qRT-PCR) was used to quantitatively analyze the gene expression changes in human dermal fibroblasts (HDFs) by hydroxytyrosol. Senescence-associated β-galactosidase (SA-β-gal) assay was implemented to dye β-galactosidases (used as a cell aging biomarker) to measure HDF cell aging by UVA. Hydroxytyrosol decreased the SA-β-galactosidase activity in a dose-dependent manner in UVA-exposed HDFs. Also, the elevated expression of MMP-1 and MMP-3 by UVA were decreased by hydroxytyrosol in a dose-dependent manner. To examine the anti-inflammatory effect of hydroxytyrosol in UV exposed HDFs, the expression of inflammatory interleukins IL-1β, IL-6, and IL-8 were analyzed. Quantitative RT-PCR showed that hydroxytyrosol decreased the expression of IL-1β, IL-6, and IL-8 gene. Through this research, we demonstrate that hydroxytyrosol has effects on anti-inflammatory and anti-aging in HDFs damaged by UVA. We suggest that hydroxytyrosol is fully worthy of using as a cosmetic material effective to anti-inflammatory and to delay cellular senescence on HDFs.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (44)
CITATIONS (46)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....